Angiogenesis, the formation of new blood vessels from preexisting vasculature, is a crucial process in cancer progression.1 Investigating the signaling pathways involved in angiogenesis, particularly those centered on vascular endothelial growth factor (VEGF), has driven the development of angiogenesis inhibitors for cancer therapy.2,3 These inhibitors impede VEGF activation by either blocking its binding to cell-surface receptors or disrupting intracellular pathways. The gene discussed is CD177; the disease is cancer.